

# Analyst

Accepted Manuscript



This article can be cited before page numbers have been issued, to do this please use: N. A. Cerusico, J. P. Aybar, S. A. Lopez, S. G. Molina, R. Chavez Jara, E. M. Sesto Cabral, J. C. Valdez, A. Ben Altabef and A. N. Ramos Vernieri, *Analyst*, 2018, DOI: 10.1039/C7AN01909B.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [author guidelines](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the ethical guidelines, outlined in our [author and reviewer resource centre](#), still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

**TITLE**

FTIR spectroscopy of chronic venous leg ulcer exudates: an approach to spectral healing marker identification.

Nicolas Cerusico<sup>a</sup>, Juan P. Aybar<sup>a</sup>, Silvana Lopez<sup>b</sup>, Silvia G. Molina<sup>b</sup>, Romina Chavez Jara<sup>a</sup>, Eugenia Sesto Cabral<sup>a</sup>, Juan C. Valdez<sup>c</sup>, Aida Ben Altabel<sup>d</sup> and Alberto N. Ramos<sup>a\*</sup>

<sup>a</sup> Laboratorio de Estudios Farmacéuticos y Biotecnología Farmacéutica. Instituto de Biotecnología Farmacéutica y Alimentaria (INBIOFAL). San Miguel de Tucumán, Tucumán. Argentina

<sup>b</sup> Servicio de Dermatología. Hospital de Clínicas Presidente Nicolás Avellaneda. San Miguel de Tucumán, Tucumán. Argentina

<sup>c</sup> Instituto de Microbiología, Facultad de Bioquímica, Química y Farmacia. Universidad Nacional de Tucumán. San Miguel de Tucumán, Tucumán. Argentina.

<sup>d</sup> INQUINOA-CONICET. Instituto de Química Física. Facultad de Bioquímica, Química y Farmacia. Universidad Nacional de Tucumán. San Miguel de Tucumán, Tucumán. Argentina.

\*Corresponding author: Alberto N. Ramos Vernieri. Av. Nestor Kirchner N° 1900. T4000CAN San Miguel de Tucumán, Tucumán. Argentina. Phone: +0054 381 4856596. [alnirave@gmail.com](mailto:alnirave@gmail.com).

Keywords: Chronic venous leg ulcers, FTIR spectroscopy, Wound exudate.

**ABSTRACT**

Chronic venous leg ulcer (CVLU) arises as a chronic venous insufficiency complication and is a major cause of morbidity throughout the world. Our hypothesis is that CVLU exudate composition is a biochemical representation of wound clinical state. Then, Fourier Transform Infrared (FTIR) spectroscopy could be a useful and less-invasive technique to study the clinical state of the ulcer. For this, the aim of this work was to perform a spectral characterization of exudate from CVLU using FTIR spectroscopy to identify potential healing markers.

45 exudate samples from CVLU, 95% of the strains isolated from CVLU in planktonic and biofilm phenotypes and other related biological samples as human plasma, serum, urine, blood cells, urea, creatinine, glucose and albumin were studied by FTIR spectroscopy. According to vibration frequency of biomolecules (lipids, protein, nucleic acids and carbohydrates) characteristic bonds at infrared region, different spectral windows were selected and spectral areas of each window were measured. Besides, Savitzky-Golay second derivative were obtained for all spectra and peaks from each standardized window were detected.

FTIR spectroscopy allowed to identify sample types (exudate, plasma, serum, urine) as each one present a unique relative composition and ratios ranges. Also, this technique could be useful to identify bacteria at phenotypic-ulcer state and allows to differentiate if bacteria are in biofilm or planktonic form which is unlikely by conventional methods.

In this work we found some spectral markers (areas, peaks) that allow to identify several parameters in exudate as: a) Total cellularity, b) Inflammatory cells load, c) Bacterial load, d) Fibrin amount, e) Inflammatory proteins. Because the measured areas or founded peaks are concentration-dependent this method could also serve to measure them.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Therefore, FTIR spectroscopy could be useful to evaluate patient evolution as all these exudate parameters represent critical negative markers for wound healing.

Analyst Accepted Manuscript

## INTRODUCTION

Fourier Transform Infrared (FTIR) spectroscopy is being increasingly used in biomedical applications with high degrees of success<sup>1-6</sup>. Molecular bonds with an electric dipole moment that can change by atomic displacement owing to natural vibrations are IR active<sup>7</sup>. These vibrational modes are quantitatively measurable by IR spectroscopy, providing a unique, label-free tool for studying molecular composition and dynamics without perturbing the sample<sup>7</sup>. FT-IR spectroscopy is a non-destructive method for the analysis of cells, tissue and fluids<sup>1-8</sup>. However, there are not reported studies of wound fluid from Chronic Venous Leg Ulcers (CVLUs) by FT-IR spectroscopy.

CVLU arises as a chronic venous insufficiency complication and is a major cause of morbidity throughout the world<sup>9-11</sup>, with an overall prevalence ranging up to 2% in the general population<sup>13</sup> and median ulcer durations that range from six - eight months to decades<sup>13</sup>.

Several factors are involved on CVLU delayed healing process: venous insufficiency degree<sup>14</sup>, infection<sup>9,15</sup>, inflammatory molecules<sup>9</sup>, etc. Due to all of these factors involved in the CVLUs development, the correct diagnostic, prognosis and its treatment are difficult, leading CVLUs to a long non-healing state<sup>16</sup>. Wound fluid or ulcer exudate may be used as a clinical state indicator, because its complex composition is reflex of the biochemical processes that occur on the wound bed and of its chronicity<sup>17,18</sup>. Exudate formation results from plasma ultrafiltrate as local inflammation consequence influenced by the wound healing process<sup>19</sup>. When the tissue is injured, inflammatory process begins along with the wound-healing process<sup>20</sup>. This promote the affluence of inflammatory cells, such as polymorphonuclears (PMN), lymphocytes, and macrophages that are key to the removal of contaminating microorganisms and infection<sup>17,20</sup>. Exudate has high viscosity and high protein

1  
2  
3 amount (>30 g/L)<sup>18</sup> and several components from serum like glucose<sup>18</sup>, urea<sup>18,21</sup>,  
4 creatinine<sup>18,21</sup>, lactate and salts<sup>18,21</sup>; tissue inflammatory molecules as cytokines, serine  
5 proteinase, cysteine proteinase, aspartic proteinase and matrix metalloproteinases  
6 (MMPs)<sup>12,17,19</sup>. Also, exudate contains bacteria and biofilm components as extracellular  
7 polysaccharide matrix (EPS)<sup>22,23</sup> and DNA<sup>24</sup>. Therefore, exudate might be considerate as a  
8 negative healing factor in chronic wounds because excessively proteolytic environment will  
9 continually degrade key growth promoting agents and thus will not allow normal wound  
10 healing to occur<sup>17</sup>. Chronic wound exudate has higher MMPs levels than acute exudate which  
11 produces tissue digestion<sup>17</sup>. There is a correlation between elevated levels of MMPs and  
12 delayed healing<sup>12,25</sup>. Also, MMP may cause inhibition of endothelial cell proliferation and  
13 angiogenesis<sup>26</sup>. Finally, exudate is a physical barrier for cell displacement in the re-  
14 epithelization process<sup>26</sup>.

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

In summary, exudate from a chronic wound contains plasma components, inflammatory cells, proteins from the inflammatory response, bacteria and components from the bacterial biofilm matrix (**Figure 1**). Our hypothesis is that exudate composition is a biochemical representation of the clinical state of a chronic wound. Therefore, FTIR spectroscopy associated to other clinical parameters could be a useful technique that provides a less-invasive and simply way to represent the clinical state of the ulcer and that allows the identification of prognosis/diagnostic markers. For this, the aim of this work was to perform a spectral characterization of exudate from CVLU using FTIR spectroscopy to identify potential healing markers.

## EXPERIMENTAL.

### 1. Ethics.

1  
2  
3 This research protocol was approved and monitored by Independent Medic Ethic Committee  
4 from Argentinian Norwest (CIEM-NOA). Patients under observation signed an informed  
5 consent before being included to this protocol.  
6  
7

## 8 2. Patients

9  
10 For the mentioned protocol, 45 patients from Dermatology Service of Nicolas Avellaneda  
11 Hospital (San Miguel de Tucuman, Tucuman – Argentina) were selected. Patients with  
12 CVLU were diagnosed by venous doppler and clinical criteria.  
13

14  
15 Inclusion criteria: a) Ulcer location: Lower-third of lower limbs. b) Both Sexes. c) Age:  
16 between 40 – 80 years. d) ulcer size: 20 to 150 cm<sup>2</sup>. e) Ulcer evolution time: 1 to 3 years  
17

18  
19 Exclusion criteria: Patients with background of 1) systemic infection, 2) cancer and/or under  
20 chemotherapy treatment, 3) autoimmune disease, 4) drugs abuse, were excluded from this  
21 study.  
22

23  
24 As relevant clinical information, patient's clinical association pathologies and ulcer evolution  
25 time were analyzed from its clinical records.  
26

## 27 3. Exudate samples

28  
29 Exudate was obtained by gentle aspiration with a syringe (without needle and avoiding to  
30 produce pain and bleeding) from 6 different points of the CVLU and stored at -20°C until  
31 processing.  
32

## 33 4. Spectral contribution controls

34  
35 In order to evaluate spectral contributions on exudate that come from plasma ultrafiltrate, the  
36 following lyophilized controls were used (Figure 1):  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Serum (n = 8): Obtained by whole blood extraction from random patients. Sera were left to  
4  
5 clot for 15 minutes and then centrifuged for 10 min at 3000 rpm.  
6

7  
8 Plasma (n = 8): Obtained by whole blood extraction from random patients on sodium citrate  
9  
10 1.2 % w/v (ratio:9/1) and centrifuged 10 min at 3000 rpm.  
11

12  
13 Free-protein serum (n = 8): This control is useful to find if there are protein contributions on  
14  
15 exudate spectra that not come from plasma, analyzing specifically at protein spectral regions.  
16  
17 Polson *et al.* protocol was followed to obtain this free-protein serum<sup>27</sup>. A serum aliquot was  
18  
19 separated and then treated with absolute ethanol 99.5% v/v (Cicarelli) (1/0.5), incubated at -  
20  
21 20°C during 12 h and then centrifuge at 8000 rpm for 20 minutes. This process was repeated  
22  
23 twice to ensure serum deproteinization and corroborated with UV spectroscopy (200 – 400  
24  
25 nm)<sup>28</sup> and Bradford method<sup>29</sup>.  
26  
27

28  
29 Urine (n = 8): Urine is a plasma ultrafiltrate and for this reason could be a useful control for  
30  
31 exudate study as a free-protein control (**Figure 1**). Urine samples were taken after day-first  
32  
33 urine from 8 volunteer human subjects in order to reduce the amount of filtered proteins to  
34  
35 the maximum. Urine samples come from 8 different human volunteers between 30 – 40 years  
36  
37 old with no kidney disease history, hepatic disease or use of chronic medication to ensure the  
38  
39 correct glomerular function. Free-cells urines were obtained by centrifugation at 3000 rpm  
40  
41 for 10 min.  
42  
43

44  
45 Blood cells control (n = 8): was used to analyze cellular contribution from inflammatory  
46  
47 response (white blood cells - WBC) and bleeding (red blood cells - RBC) on exudate (**Figure**  
48  
49 **1**). To obtain this control, a whole blood anticoagulated (citrate 1.2% w/v) aliquot was  
50  
51 separated and centrifuged at 3000 rpm for 10 min, then plasma was separated and remaining  
52  
53 cells (WBC + RBC) were washed with saline three times. Finally, cells were re-suspended in  
54  
55 saline and stored at 4 °C until its processing.  
56  
57



Other serum controls: Different controls were carried out to analyze individual contributions of most important seric molecules (**Figure 1**). Glucose (Cicarelli-Argentina), Urea (Cicarelli-Argentina), Creatinine (Anedra-Argentina) and inorganic  $\text{H}_2\text{PO}_4^{1-}/\text{HPO}_4^{2-}$  mix (Cicarelli-Argentina), Human Albumin (Sigma-Aldrich-USA) were used as individual drug controls.

To corroborate protein amount and confirm the origin of the protein contributions on spectra, two assays for protein determination were performed over albumin, urea, creatinine, urine, free-protein serum and serum controls: UV spectra obtained at 200 – 400 nm<sup>26</sup> and Bradford method<sup>27</sup>.

## 5. Bacteria

To find bacterial contributions on exudate FTIR spectra (**Figure 1**), strains isolated from CVLU were studied in its planktonic and biofilm forms. Selected strains were isolated from CVLU exudate samples by conventional methods and represent 95% of the aerobic isolations<sup>16,31,32</sup>. Isolated Gram-positive bacteria were: *Staphylococcus aureus*, Methicillin Resistance *S. aureus* (MRSA), *S. haemolyticus*, Coagulase Negative Staphylococcus (CNS), *Beta-hemolytic Streptococcus* and *Enterococcus faecalis*. Isolated Gram-negative bacteria were: *Pseudomonas aeruginosa*, *Pseudomonas sp*, *Escherichia coli*, *Serratia marscecens*, *Proteus mirabilis*, *Enterobacter aerogenes*, *Enterobacter sp*, *Klebsiella pneumoniae*, *Burkholderia cepacia*, *Providencia sp* and *Citrobacter sp*. All bacteria were stored at -20°C in BHI media + glycerol (30%).

Planktonic form: Each strain was activated at room temperature for 30 min, cultured in BHI broth and then incubated for 6 h at 37°C. Cultures were centrifuged at 8000 rpm for 10 min and planktonic cells pellets were washed 3 times (saline) to remove culture medium. Planktonic pellet was lyophilized before its spectroscopic study.

1  
2  
3 Biofilm formation: Each strain was activated at room temperature for 30 min, cultured in BHI  
4 broth or BHI broth (plus 5 % v/v) human serum for nutritionally highly demanding bacteria)  
5 (1/10 v/v) and then incubated 37°C until biofilm formation (12 to 24 h depending on the  
6 strain). In some cases, bacteria were stressed to allow biofilm formation (nutritional stress,  
7 UV radiation, thermic stress). Cultures were centrifuged at 3000 rpm for 10 min (to obtain  
8 mainly a biofilm pellet). Biofilm pellets were washed 3 times (saline) to remove culture  
9 medium and planktonic bacteria. Biofilm pellet was lyophilized before its spectroscopic  
10 study.

## 11 6. FTIR Spectroscopy

12 To collect FTIR spectra, a Perkin-Elmer GX 1 spectrophotometer was used. Exudate samples  
13 and controls were processed as liquid samples, 5  $\mu\text{l}$  of exudate sample and controls were  
14 dried by  $\text{N}_2$  flow and vacuum over AgCl circular optical windows. Planktonic and biofilm  
15 bacteria were processed for duplicate as solid samples on KBr pills of spectroscopic grade  
16 (1:20). Spectra were collected with 64 scans and a  $4\text{cm}^{-1}$  of resolution in the range of mid-  
17 infrared  $4000\text{ cm}^{-1} - 400\text{ cm}^{-1}$ . For spectral pre-processing: smoothing, baseline correction  
18 and normalization with Amide I band were used. Pre-processing is useful to compensate  
19 differences in sample quantity or a different optical pathlength<sup>7,32</sup>.

### 20 6.1 Infrared regions

21 According to vibration frequency of main biomolecule bonds<sup>2,7,33,34</sup>, different spectral  
22 windows were selected according to main bonds characteristic of each biomolecule: W1:  
23  $\text{CH}_3$  and  $>\text{CH}_2$  of Lipids ( $2800-3000\text{ cm}^{-1}$ ); W2: Ester bonds ( $1770-1720\text{ cm}^{-1}$ ); W3: Amide  
24 I ( $1700-1600\text{ cm}^{-1}$ ); W4: Amide II ( $1600-1480\text{ cm}^{-1}$ ); W5: Phosphates of nucleic acids  
25 ( $1270-1190\text{ cm}^{-1}$ ); W6: Carbohydrate bonds of polysaccharides ( $1190-900\text{ cm}^{-1}$ ). Mixed  
26 region ( $1480-1280\text{ cm}^{-1}$ ), unspecific region ( $4000-3000\text{ cm}^{-1}$ ) and fingerprint region ( $900-$

400  $\text{cm}^{-1}$ ) were not taken into account for this study (**Figure 2**). **Table 1** shows the proposed assignments for different biomolecules studied.

## 6.2 Spectral Area.

Spectral area was measured by OMNIC 8.0 software at all standardized biomolecules windows of each normalized spectrum. Total spectral area corresponds to the sum of the individual area values. From these measurements, different ratios values were calculated and percentages of biomolecules showed on spectra were estimated.

## 6.3 Second derivative.

Second derivative Savitzky-Golay (SG) (9 points and order 3) were obtained by OMNIC 8.0 software for all spectra. Each standardized biomolecule window was analyzed to find peaks in its corresponding region. As selection criteria 100% of sensitivity and threshold of 0.010 were used for peaks selection (software parameters). Before second derivative obtaining, the original absorbance spectra were previously converted to transmittance units in order to match the second derivative peaks with the original spectrum bands (software requirement for peak selection).

## 7. Statistics

Statistical significance was evaluated using the Mann-Whitney-Wilcoxon U test for non-parametrical variables. Data analysis was performed with GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA).

## RESULTS AND DISCUSSION.

### 1. Exudate, plasma, serum, free-protein serum and urine spectral areas

In this study, relative composition of each biological polymer in exudates and controls (serum, plasma, free-protein serum, urine, blood cells and other related controls) (**Figure 3 a-**

1  
2  
3 I) were studied by measurement of spectral areas and ratios between them. Also It was found  
4 that each analyzed sample by FTIR (exudates and controls) show a unique relative  
5 composition and ratios. This could be used to identify sample types (exudates, plasmas,  
6 serum, urine) (Figure 4). Table 2 shows relative composition of each exudate.

### 1.1 CH<sub>3</sub> / CH<sub>2</sub> window (lipids)

2  
3 These areas are mainly determined by C-H asymmetric and symmetric stretching of >CH<sub>2</sub>  
4 and CH<sub>3</sub> groups, that are typically present on fatty acids and lipids in biological samples.  
5 (Table 1). There are no significant differences between spectral areas of exudate and plasma,  
6 serum, free-protein serum and cells which indicates a similar lipid concentration (Figure 4).  
7 In these samples, fatty acids and lipids are possibly represented by membrane phospholipids  
8 from prokaryotic and eukaryotic cells and/or from VLDL, LDL, HDL and chylomicrons<sup>35</sup>. In  
9 exudates, we expect contributions mainly from cell membrane lipids, which was  
10 demonstrated by the great similarity of areas between exudates and cells (Figure 4).  
11 Therefore, exudate cellularity could be estimated from this window area. Logically, urines do  
12 not have absorbance in this region, not only because are free-cell urines but also because are  
13 free from lipoprotein.

14  
15 Oppositely, albumin have C-H asymmetric and symmetric stretching of >CH<sub>2</sub> and CH<sub>3</sub> from  
16 its hydrocarbon chain.

### 1.2 Ester bonds window (lipids)

17  
18 This area is mainly determined by >C=O stretch of ester bonds in fatty acids (Table 1).  
19 Exudates and free-protein serum were the only samples that showed this spectral band  
20 (Figure 4). In the case of exudates, the presence of this band (and the associated peaks in  
21 second derivative) could represent membrane phospholipids concentration in the sample.  
22 Moreover, free- protein serum controls exhibit absorbance, which may be due to ester bond  
23 formation by the alcohol used during deproteinization method.

### 1.3 Amide I and amide II windows (Proteins)

Amide I areas are mainly determined by  $>C=O$  stretching of peptidic bond of proteins and peptides, followed by C-N swinging and other vibrations of secondary protein structure components. Amide II areas are mainly determined by vibrations of NH bend, C-N stretch, CO bend and N-C stretch (Table 1).

The protein absence of free-protein controls, like free-protein serum and urine, was demonstrated by UV spectra (**Figure 5**) and Bradford method (data not shown). These samples show lower amide I areas respect exudate, serum and plasma ( $p < 0.001$ ). However, despite being free-protein samples, still having absorbance in amide I window (**Figure 4**). This might be caused by the contribution of C=O stretch and N-H stretch and deformation of urea<sup>36</sup>, strong C=O stretch, C-C-N bending of creatinine bonds<sup>37</sup> as urea and creatinine spectra also showed (**Figure 3h and 3j**).

It was previously demonstrated that wound fluid protein concentration (measured by biochemical methods) is lower than serum protein concentration<sup>18,21</sup>. However, there were no significant differences between amide I areas of exudate, serum and plasma (**Figure 4**). As all these samples have similar concentrations of urea and creatinine<sup>18,21</sup>, this would indicate also a similar protein concentration which is not correct. This may be due to in amide I region contribution of the inflammatory, bacterial and serum proteins all together on exudates were detected. This compensates the difference detected by biochemical methods that only measure inflammatory and seric proteins<sup>18,21</sup>.

Amide II areas represent the real protein content of the samples, because free-protein serum and urine show null or minimum absorbance and serum and plasma were significantly higher than exudate ( $p < 0.001$ ) as expected (**Figure 4**).

### 1.4 Phosphates windows (nucleic acids)

1  
2  
3 In this window, areas are mainly determined by  $>PO_2^-$  stretch absorbance present in RNA and  
4 DNA (Table 1). However, in this region also may be present vibrations of NH bend, C-C  
5 stretch, C-N stretch and CO bend of the called Amide III<sup>2</sup>.  
6  
7

8  
9  
10 Urine and free-protein serum show null absorbance in this region, which is logic as both  
11 samples are DNA/RNA/protein free (Figure 4 – Phosphate bonds). In contrast, areas observed  
12 in serum and plasma could be caused by proteins while the observed areas in cells and  
13 exudates could be as a result of to the sum of nucleic acids and proteins. Taking into account  
14 that: 1) exudate protein content is lower than serum protein content (Figure 4 – Amide II)<sup>18,21</sup>;  
15 2) there is no significant differences between phosphate bonds as there are in serum and  
16 exudate, and 3) phosphate areas in cells are significantly lower than phosphate areas in  
17 exudates ( $p < 0.001$ ); we could assume that the difference between phosphate areas from  
18 exudates and cells are mainly determined by nucleic acids indirectly related to exudate  
19 cellularity (Figure 4 – Phosphate bonds).  
20  
21

### 22 **1.5 Carbohydrate bonds (Polysaccharides)**

23 In this window, areas are mainly determined by C-O, C-C stretch, C-O-H, C-O-C  
24 deformation of carbohydrates or C-OH stretch of serine, threonine, tyrosine in proteins (Table  
25 1).  
26  
27

28  
29 On serum and plasma, areas values probably came from vibrational modes of glycoproteins,  
30 glucose and other sugars. Cells presented absorbance because of membrane glycoproteins  
31 presence. Albumin has absorbance in this window because C-OH stretch and vibrational  
32 modes of serine, threonine and tyrosine<sup>2</sup>. On exudates, areas values probably came from  
33 vibrational modes of cellular glycoproteins, glucose, seric glycoproteins, lipopolysaccharides  
34 from planktonic bacteria and exopolysaccharides from bacterial biofilm matrix. There is an  
35 important variability in polysaccharides concentration among all samples which is  
36 demonstrated by the elevated standard deviation (SD) in polysaccharides area from exudate  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56

1  
2  
3 samples (Figure 4 – Carbohydrate bonds). Taking into account that all controls present low  
4 SD we could assume that the elevated SD in exudates may be due to different biofilm matrix  
5 exopolysaccharides contribution from infecting bacteria<sup>23,33</sup>. Because of this polysaccharides  
6 areas in exudates could indirectly represent its biofilm load.

7  
8 Free-protein serum carbohydrates areas was significantly higher than exudates areas  
9 ( $p < 0.001$ ). This may be due to spectral contributions of remnant alcohol (C-OH) from  
10 deproteinization method (**Figure 3l and 4**).

## 11 **2. Spectral areas of bacteria**

12 We analyzed 95% of the aerobic clinical isolates<sup>16</sup> from CVLU exudates. Each strain showed  
13 a unique relative composition for planktonic and biofilm phenotypes (**Table 3**). This could be  
14 useful to identify bacteria at phenotypic-ulcer state. Also allow to differentiate if bacteria are  
15 in biofilm or planktonic phenotype, which is unlikely by conventional methods. Besides, as  
16 mentioned above, a broad variability among polysaccharides areas for all bacteria spectra  
17 were observed. This could be as result of the different exopolysaccharides composition in  
18 each case.

## 19 **3. Peaks**

20 A deep study of the peaks founded in 2nd derivative spectra from exudate samples, controls  
21 and bacteria in both phenotypes was performed. Here we only show the typical sample peaks  
22 that could have clinical significance.

23 In the CH<sub>3</sub>/CH<sub>2</sub> region (W1) a characteristic peak at  $\sim 2933 \text{ cm}^{-1}$  was founded on exudate  
24 spectra (100%) and on blood cells spectra (100%). This peak could represent the presence of  
25 cellular membrane phospholipids from inflammatory cells since this peak is absent in bacteria  
26 and controls.





for antisymmetric  $\text{PO}_2^-$  stretch<sup>37</sup>. Therefore, these peaks could represent prokaryotic/eukaryotic load in the sample as both are present in exudates.

In the carbohydrates bonds region (W6) an extraordinary variability of peaks was founded. There are only a few peaks that were sample-characteristic as  $1171\text{-}1174\text{ cm}^{-1}$  for exudate (100%) and  $1097\text{-}1093\text{ cm}^{-1}$  for biofilm and planktonic bacteria (100%). The rest of the founded peaks might represent the variability produced by biofilm matrix exopolysaccharides and glycoproteins in exudates and glycoproteins in plasma and serum.

## CONCLUSION

FTIR spectroscopy allows to identify sample types (exudates, plasmas, serum, urine, planktonic bacteria, biofilm bacteria) as each one present a unique relative composition and ratios ranges. Also, this technique could be useful to identify bacteria at phenotypic-ulcer state and allows to differentiate if bacteria are in biofilm or planktonic form which is unlikely to do so by conventional methods.

Because the measured areas or the located peaks are concentration-dependent, this method could serve to study several parameters in exudate as:

### 1) Exudate cellularity

- a) Total cellularity could be estimated from the  $\text{CH}_3 / \text{CH}_2$  window area.
- b) Inflammatory cells load could be estimated from ester bonds window area or by measuring  $2933\text{ cm}^{-1}$  and/or  $1236\text{-}1234\text{ cm}^{-1}$  peak areas from 2nd derivative (SG).
- c) Bacterial load could be estimated by measuring  $1716\text{-}1713\text{ cm}^{-1}$  and/or  $1244 - 1242\text{ cm}^{-1}$  peak areas from 2nd derivative (SG).

### 2) Exudate total protein content

- a) In complex human fluid samples like exudates, urine, serum or plasma is advisable to use amide II areas to estimate total protein content.

1  
2  
3 d) Fibrin amount could be estimated by measuring 1690  $\text{cm}^{-1}$  peak area from 2nd derivative  
4 (SG).  
5

6  
7 b) Inflammatory proteins could be estimated by measuring 1682-1680  $\text{cm}^{-1}$  and/or 1262-1260  
8  $\text{cm}^{-1}$  peak areas from 2nd derivative (SG).  
9

10  
11 3) Exudate biofilm load could be indirectly estimated by measuring carbohydrate bonds area.  
12

13 All of these exudate parameters could be useful to evaluate patient evolution as cells and  
14 proteins from inflammatory response, fibrin and planktonic or biofilm bacterial load represent  
15 critical negative markers for wound healing. Hence, FTIR spectroscopy could be a useful  
16 technique that provides a less-invasive and simple way to represent the clinical state of the  
17 wound.  
18

19 In the future, the use of other spectral contribution controls could allow the identification of  
20 more specific markers in exudate. For example, hemoglobin as bleeding marker, purified  
21 specific phospholipids from eukaryotic membranes as inflammatory cellularity marker,  
22 lipopolysaccharides and peptidoglycan as bacterial cellularity marker, matrix  
23 metalloproteinases (MMP-2, MMP-8, MMP-9) as protease activity markers and different  
24 exopolysaccharides from bacterial biofilm matrix (i.e. alginate) as specific biofilm infection  
25 marker.  
26  
27  
28

### 29 **ACKNOWLEDGEMENTS**

30  
31 This work was supported by grants: BID 3664 PICT 2014, BID 2530 PICT 2014 and D-TEC  
32 0022/2013 from National Agency for Scientific and Technological Promotion, Argentina.  
33  
34

35  
36 **Conflict of interest disclosure:** The authors declare no competing financial interest.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**REFERENCES.**

1. K. Gajjar, J. Trevisan, G. Owens, P. J. Keating, N. J. Wood, H. F. Stringfellow, P. L. Martin-Hirsch and F. L. Martin, *Analyst*, 2013, **138**, 3917-3926.
2. M.J. Baker, E. Gazi, M.D. Brown, J.H. Shanks, P. Gardner and N.W., *Br J Cancer*, 2008, **99** (11), 1859-1866.
3. B. Singh, R. Gautam, S. Kumar, B. N. Vinay Kumar, U. Nongthomba, D. Nandi, G. Mukherjee, V. Santosh, K. Somasundaram and S. Umapathy, *Curr Sci*. 2012, **102** (2), 232-244.
4. C. Petibois and B. Desbat, *Trends Biotechnol*, 2010, **28** (10), 495-500.
5. P. D. Lewis, K. E. Lewis, R. Ghosal, S. Bayliss, A. J. Lloyd, J. Wills, R. Godfrey, P. Kloer and L. AJ Mur, *BMC Cancer*, 2010, **10** (1), 640-670.
6. J. Ollesch, S.L. Drees, H.M. Heise, T. Behrens, T. Brüning and K. Gerwert, *Analyst*. 2013, **138** (14), 4092-4102.
7. M. J. Baker, J. Trevisan, P. Bassan, R. Bhargava, H. J. Butler, K. M. Dorling, P. R. Fielden, S. W. Fogarty, N. J. Fullwood, K. A. Heys, C. Hughes, P. Lasch, P. L. Martin-Hirsch, B. Obinaju, G. D. Sockalingum, J. Sulé-Suso, R. J. Strong, M. J. Walsh, B. R. Wood, P. Gardner and F. L. Martin, *Nature protocols*, 2014, **9** (8), 1771-1791.
8. R.K. Sahu and S. Mordechai, *Future Oncol*, 2005, **1** (5), 635-647.
9. R. Serra, R. Grande, G. Buffone, V. Molinari, P. Perri, A. Perri, B. Amato, M. Colosimo and S. de Franciscis, *Int Wound J*, 2016, **13** (1), 53-58.
10. G.A. Rahman, I.A. Adigun and A. Fadeyi, *Ann Afr Med.*, 2010, **9**, 1-4.
11. G. Lazarus, M. Fran Valle, M. Malas, U. Qazi, N. M. Maruthur, D. Doggett, O. A. Fawole, E. B. Bass and J. Zenilman, *Wound Repair Regen.*, 2014, **22** (1), 34-42.
12. R. Serra, G. Buffone, D. Falcone, V. Molinari, M. Scaramuzzino, L. Gallelli and S. de Franciscis, *Wound Repair Regen.*, 2013, **21** (3), 395-401.

- 1  
2  
3 13. Edwards H, Finlayson K, Skerman H, Alexander K, Miaskowski C, Aouizerat B and Gibb M.  
4 Identification of symptom clusters in patients with chronic venous leg ulcers. *J Pain Symptom*  
5 *Manage.* 2014;47(5):867-75.  
6  
7 14. R.T. Emalberhardt and J.D. Raffetto, *Circulation*, 2005, **111** (18), 2398-2409.  
8  
9 15. K. Gjødsbøl, J.J. Christensen, T. Karlsmark, B. Jørgensen, B.M. Klein and K. Krogfelt, *Int Wound*  
10 *J.* 2006, **3** (3), 225-231.  
11  
12 16. S.V. Agale, *Ulcers-Hindawi Publ Corp.* 2013, **2013**,1-9.  
13  
14 17. A.D. Widgerow, *Wound Repair Regen*, 2011, **19** (3), 287-291.  
15  
16 18. N.J. Trengove, S.R. Langton and M.C. Stacey, *Wound Repair Regen.*, 1996, **4** (2), 234-239.  
17  
18 19. K.F. Cutting, *Br J Community Nurs.*, 2003, **8** (3), 4-9.  
19  
20 20. A.J Signer and R.A. Clark, *N Engl J Med.* 1999, **341**, 738-746.  
21  
22 21. T.J. James, M. Hughes, G.W. Cherry and R.P. Taylor, *Wound Repair Regen*, 2000, **8** (4), 264-269.  
23  
24 22. D. Metcalf and P. Bowler, *Burn Trauma*, 2013, **1** (1), 5-12.  
25  
26 23. I.W. Sutherland, *Microbiology*, 2001, **147** (1), 3-9.  
27  
28 24. V. Papayannopoulos and A. Zychlinsky, *Trends Immunol.*, 2009, **30** (11), 513-521.  
29  
30 25. J.C. McDaniel, S. Roy and T. Wilgus, *Wound Repair Regen.*, 2013, **21** (3), 339-351.  
31  
32 26. B. Amato, G. Coretti, R. Compagna, M. Amato, G. Buffone, D. Gigliotti, R. Grande, R. Serra and  
33 S. de Franciscis, *Int Wound J*, 2015, **12** (6), 641-645.  
34  
35 27. C. Polson, P. Sarkar, B. Incledon, V. Raguvaran and R. Grant, *J Chromatography B*, 2003, **785**  
36 (2), 263-275.  
37  
38 28. C.N. Pace, F. Vajdos, L. Fee, G. Grimsley and T. Gray, *Protein Sci.*, 1995, **4** (11), 2411-2423.  
39  
40 29. W. Gebauer, *Els*, 2002, 2-4.  
41  
42 30. K. Kirketerp-Møller, P. Ø. Jensen, M. Fazli, K. G. Madsen, J. Pedersen, C. Moser, T. Tolker-  
43 Nielsen, N. Høiby, M. Givskov and T. Bjarnsholt, *J Clin Microbiol.*, 2008, **46** (8), 2717-2722.  
44  
45 31. D.D. Rhoads, R.D. Wolcott, Y. Sun and S.E. Dowd, *Int J Mol Sci.*, 2012, **13** (3), 2535-2550.  
46  
47 32. P. Lasch, *Chem and Intel Lab Syst*, 2012, **117**, 100-114.  
48  
49 33. A. Bosch, D. Serra, C. Prieto, J. Schmitt, D. Naumann and O. Yantorno, *Appl Microbiol*  
50 *Biotechnol*, 2006, **71** (5), 736-747.  
51  
52 34. D. Naumann and P. Lasch. *Biomedical Spectroscopy. Encyclopedia of analytical chemistry*, ed.  
53 Wiley J & Sons, 2015.  
54  
55 35. K. Liu, R.A. Shaw, A. Man, T.C. Dembinski and H.H. Mantsch, *Clin. Chem*, 2002, **48** (3), 499-  
56 506.  
57  
58 36. M. Khanmohammadi, K. Ghasemi, A.B. Garmarudi and M. Ramin, *Spectrochim ACTA PART A:*  
59 *Mol Biomol Spectrosc.* 2014.  
60

37. M. Banyay, M. Sarkar, A. Graslund, *Biophys Chem*, 2003, **104**, :477–488.

## TABLES

Window	Denomination	Wavenumber (cm <sup>-1</sup> )	Proposed vibrational mode	Proposed primary source
W1	CH <sub>3</sub> ; CH <sub>2</sub>	3000 - 2800	C-H asymmetric and symmetric stretch of >CH <sub>2</sub> and CH <sub>3</sub> present on fatty acids and lipids	Lipids, membrane phospholipids.
W2	Ester bonds	1770 - 1720	>C=O stretch of ester bonds in fatty acids	Lipids, membrane phospholipids.
W3	Amide I	1715 - 1600	>C=O stretch, C-N stretch, CCN deformation in peptide bonds	Proteins and peptides
W4	Amide II	1600 - 1480	NH bend, C-N stretch, CO bend, N-C stretch	Proteins and peptides
W5	Phosphate bonds	1270 - 1200	>PO <sub>2</sub> <sup>-</sup> stretch in RNA/DNA or NH bend, C-C stretch, C-N stretch, CO bend (Amide III)	Nucleic acids and proteins.
W6	Carbohydrates bonds	1190 - 900	C-O, C-C stretch, C-O-H, C-O-C deformation of carbohydrates or >PO <sub>2</sub> <sup>-</sup> sym. stretch of phosphodiester group in nucleic acids	Carbohydrates, polysaccharides and nucleic acids

**Table 1.** Proposed vibrational modes at different frequencies to define work regions (windows) in this study<sup>1,2,3,5,7,32,33</sup>. The primary source proposed are biomolecules which present high particular bonds amount that present absorbance at each window. That allow

1  
2  
3 define each region as a windows where a particular biomolecule concentration could be  
4  
5 measured.  
6  
7

8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Analyst Accepted Manuscript

Exudate	W1	W2	W3	W4	W5	W6
001	11.21	0.58	22.18	12.19	2.29	14.81
002	13.50	0.00	23.56	11.67	3.37	13.63
003	11.70	0.00	27.12	10.00	1.50	16.27
004	12.97	0.00	32.90	15.00	3.31	18.16
005	19.66	1.75	28.02	16.17	2.90	17.82
006	16.12	0.83	29.76	15.24	3.71	24.66
007	20.07	1.76	34.26	14.82	3.95	28.06
008	18.60	1.53	34.36	14.15	4.13	29.37
009	9.59	0.00	36.95	17.42	1.85	5.68
010	8.61	0.00	35.14	15.83	1.54	4.50
011	14.88	0.23	36.02	17.70	2.61	16.84
012	32.68	4.81	36.60	17.43	4.37	25.49
013	16.99	0.00	37.22	19.65	2.39	13.34
014	11.78	0.02	38.12	16.93	3.31	22.36
015	19.69	0.64	28.68	14.63	2.78	17.02
016	26.54	3.50	33.72	18.72	2.76	12.71
017	10.37	0.00	49.91	22.36	1.83	4.88
018	7.77	0.04	29.77	16.01	1.61	9.07
019	19.84	0.15	32.69	15.91	5.90	42.69
020	14.25	0.00	33.23	17.01	3.61	22.10
021	17.36	0.36	36.55	19.44	2.99	21.10
022	17.92	0.16	39.36	18.69	3.92	20.08
023	12.84	0.01	36.39	17.13	2.87	16.66
024	12.01	0.37	26.85	11.67	0.95	14.60
025	7.97	0.12	33.30	16.95	1.59	8.09
026	15.97	0.15	38.86	20.65	2.96	21.05
027	10.74	0.00	35.82	16.84	2.28	26.92
028	9.75	0.05	35.51	16.51	1.35	17.98
029	18.99	0.55	37.06	15.54	5.11	44.04
030	12.19	0.00	39.63	18.19	1.86	10.47
031	10.21	0.00	39.11	17.10	1.22	9.64
032	8.41	0.00	40.35	18.98	1.96	38.19
033	20.10	0.00	34.04	11.59	2.42	49.04
034	9.26	0.00	27.40	13.17	0.97	10.98
035	10.89	0.05	35.85	17.67	2.85	15.27
036	6.67	0.00	35.11	17.32	1.32	6.38
037	8.60	0.09	35.45	13.34	2.09	15.94
038	10.57	0.05	32.84	12.97	1.17	24.31
039	10.14	0.00	35.38	17.76	2.21	27.06
040	7.64	0.00	38.39	21.18	1.75	5.09
041	9.45	0.02	42.22	20.88	2.91	13.17
042	17.02	0.33	36.76	17.06	3.78	29.22
043	9.44	0.09	36.24	16.67	1.62	22.28
044	26.60	2.41	26.04	7.17	1.97	42.22
045	14.62	0.82	38.72	18.44	4.77	35.42
Mean	14.05	0.48	34.52	16.26	2.63	20.10
SD	5.64	0.98	5.13	3.05	1.15	11.06
MIN	6.67	0.00	22.18	7.17	0.95	4.50
MAX	32.68	4.81	49.91	22.36	5.90	49.04

**Table 2.** FTIR spectral characterization of exudates. The observed values correspond to relative spectral areas in each window and therefore represent exudate biopolymers relative composition.

	<b>Bacteria</b>	<b>W1</b>	<b>W3</b>	<b>W4</b>	<b>W5</b>	<b>W6</b>	<b>2<sup>nd</sup> derivative peaks</b>
<b>Planktonic phenotype</b>	<i>Staphylococcus haemolyticus</i>	10.22	65.80	1.35	17.12	43.73	<b>1750, 1095</b>
	<i>Staphylococcus aureus</i>	22.30	42.22	6.77	21.52	97.23	<b>1259, 1239, 1090</b>
	MRSA	17.11	55.06	9.02	11.66	54.63	<b>968</b>
	<i>Enterococcus faecalis</i>	12.76	48.41	14.02	18.00	40.53	<b>1719, 1614, 1546, 1074</b>
	<i>Enterococcus faecalis</i>	25.52	56.20	7.09	11.27	65.84	<b>1719, 1090</b>
	<i>Beta-hemolytic Streptococcus</i>	7.06	45.64	10.08	3.70	42.39	<b>1695, 1545, 1230, 1078, 1015, 970</b>
	<i>Proteus mirabilis</i>	13.69	47.82	12.77	8.09	30.82	<b>1060</b>
	<i>Proteus mirabilis</i>	12.97	49.84	16.28	6.56	30.02	-
	<i>Enterobacter sp.</i>	12.45	58.33	16.7	8.34	31.88	-
	<i>Enterobacter aerogenes</i>	16.43	56.51	10.65	8.60	56.45	-
	<i>Pseudomona sp.</i>	14.93	53.93	13.28	9.77	53.02	<b>1731, 1227, 1177, 1127</b>
	<i>Pseudomona sp.</i>	12.82	50.22	10.18	4.70	37.13	<b>1731, 1227, 1097</b>
	<i>Pseudomona. aeruginosa</i>	25,50	50,20	3,00	3,90	44,70	<b>1665</b>
	<i>Providencia sp.</i>	8.91	45.65	9.96	4.68	20.31	-
	<i>Citrobacter sp.</i>	13.75	49.88	13.85	5.63	36.25	<b>1716</b>
	<i>Klebsiella pneumoniae</i>	13.45	45.30	12.02	5.53	40.96	<b>1641</b>
<i>Klebsiella pneumoniae</i>	16.74	53.97	8.92	6.90	59.65	<b>1641</b>	
<i>Serratia marcescens</i>	17.29	55.37	15.08	8.90	36.78	<b>2874</b>	
<i>Escherichia coli</i>	9.79	48.46	15.66	4.89	23.08	<b>1236, 1120</b>	
<i>Escherichia coli</i>	14.98	33.81	14.99	5.45	36.82	<b>1236, 1120</b>	
<i>Burkholderia cepacia</i>	15.26	56.20	18.16	7.97	29.43	-	
<b>Biofilm phenotype</b>	<i>Staphylococcus haemolyticus</i>	12.95	56.15	17.60	8.44	33.67	-
	<i>Staphylococcus aureus</i>	15.09	56.79	15.04	9.36	47.67	<b>2744, 984</b>
	<i>Beta-hemolytic Streptococcus</i>	14.05	61.75	13.69	7.44	52.79	<b>969</b>
	<i>Beta-hemolytic Streptococcus</i>	11.12	34.2	13.25	6.57	45.63	<b>969</b>
	<i>Enterococcus faecalis</i>	13.08	45.26	12.02	7.10	41.70	<b>1634, 1212</b>
	<i>Enterococcus faecalis</i>	20.31	49.39	5.45	10.92	95.41	<b>1212</b>
	MRSA	13.78	59.48	12.17	8.01	50.41	-
	MR-CNS	9.90	34.04	11.36	5.63	44.37	<b>1075</b>
	CNS	10.04	61.39	8.58	11.83	41.58	<b>971</b>
	<i>Proteus mirabilis</i>	13.08	58.88	15.17	8.00	30.20	<b>1511, 1637, 1619, 1238, 1089</b>
	<i>Proteus mirabilis</i>	13.07	47.27	14.23	4.415	27.34	<b>1511, 1637, 1619, 1238, 922</b>
	<i>Enterobacter sp</i>	14.89	46.87	16.23	8.23	24.29	-
	<i>Enterobacter aerogenes</i>	16.47	48.02	13.50	11.14	77.33	-
	<i>Pseudomona aeruginosa</i>	17,00	43,80	11,30	6,90	27,20	<b>1085</b>
	<i>Pseudomona sp.</i>	14.33	45.83	16.60	5.74	28.29	<b>1223</b>
	<i>Pseudomona sp.</i>	16.55	55.84	17.32	7.77	34.7	-
<i>Citrobacter sp.</i>	10.24	47.99	10.77	5.20	26.76	-	
<i>Klebsiella penumoniae</i>	15.48	47.55	12.19	8.39	49.68	<b>2873, 1163, 1104, 1068, 990</b>	
<i>Klebsiella penumoniae</i>	16.97	49.61	11.50	7.70	57.43	<b>2873</b>	
<i>Escherichia coli</i>	11.55	50.5	16.40	6.54	30.43	-	
<i>Burkholderia cepacia</i>	12.53	47.76	15.5	5.39	25.25	-	



**Table 3.** FTIR spectral characterization of bacteria. The observed values correspond to relative spectral areas in each window and therefore represent bacterial biopolymers relative composition in planktonic and biofilm phenotype. Also, the table shows second derivative peaks that were present only in such strains.

Analyst Accepted Manuscript